Jon Stonehouse

CEO, BioCryst Pharmaceuticals
Durham, North Carolina,United States
Find Jon Stonehouse's Email
Find Jon Stonehouse's Phone

Who Is Jon Stonehouse?

Total Experience35 years
CompanyBioCryst Pharmaceuticals
CountryUnited States

Jon Stonehouse is the President and Chief Executive Officer of BioCryst Pharmaceuticals, a role he has held since 2007. With over three decades of experience in the biopharmaceutical industry, he has been instrumental in transforming BioCryst into a commercial-stage company dedicated to developing novel, oral, small-molecule medicines for rare diseases. Before joining BioCryst, Stonehouse served as Senior Vice President of Corporate Development at Merck KGaA, where he managed licensing, M&A, and strategic planning. His leadership at BioCryst is defined by a deep focus on patient needs, strategic financial management, and successfully guiding the company through critical clinical and regulatory milestones, most notably the global launch of ORLADEYO®.

Jon Stonehouse LinkedIn pageCompany Website

How Did Jon Stonehouse's Career Path Shape Their Journey?

Jon Stonehouse's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:

BioCryst Pharmaceuticals - CEO(2007 to Present)
Merck KGaA - Corporate Development(2002 to 2006)
EMD Pharmaceuticals - VP Strategy and L&BD(2000 to 2002)
AstraZeneca - Product Director Prilosec(1998 to 1999)
Astra Merck - National Sales Manager(1992 to 1997)
Merck - Sales(1987 to 1992)

What Are Jon Stonehouse's Key Achievements?

Leadership in Commercial Transformation

Successfully guided BioCryst from a clinical-development company to a commercial-stage organization through the global launch of its flagship product, ORLADEYO® (berotralstat), for the treatment of hereditary angioedema (HAE).

Strategic Capital Acquisition

Spearheaded major non-dilutive financing agreements, including a pivotal royalty financing deal, securing substantial capital to fund the company's research pipeline and commercial activities while protecting shareholder value.

Pipeline Advancement in Rare Diseases

Championed the strategic direction of the company to focus exclusively on developing oral medications for rare and serious diseases, significantly advancing the clinical pipeline, including promising candidates for complement-mediated diseases.

What's Jon Stonehouse's Educational Background?

.Bachelor of Science, Microbiology

University of Minnesota-Twin Cities

Buying Intent Signals for Jon Stonehouse

Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance

Company Overview

BioCryst Pharmaceuticals
Total employees503
HeadquartersDurham
Founded1986

BioCryst Pharmaceuticals is a commercial-stage biotechnology company dedicated to discovering, developing, and commercializing novel, oral, small-molecule medicines for rare and serious diseases. Leveraging its expertise in structure-guided drug design, the company's primary focus is on oral therapies that can improve the lives of patients. Their flagship product, ORLADEYO® (berotralstat), is an oral, once-daily therapy for preventing attacks in patients with hereditary angioedema (HAE). BioCryst also developed and commercialized RAPIVAB® (peramivir injection) for the treatment of acute uncomplicated influenza.

Company Website
BioCryst Pharmaceuticals Stock Information
BioCryst Pharmaceuticals, Inc. is listed on the NASDAQ under the ticker symbol BCRX. The company went public on March 2, 1994

Highperformr's free tools for company research

Find contact info

Get verified emails, phone numbers, and LinkedIn profile details

Find similar contacts

Discover contacts with similar roles, seniority, or companies

Perform deep contact research

Uncover insights like skills, work history, social links, and more

Discover, research and enrich contacts with Highperformr — Smarter, Faster

Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.

Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.

  • Track signals like job change, promotion, and LinkedIn activity
  • Enrich contacts with verified email, phone, and social data instantly
  • Automate enrichment and updates with powerful workflows
  • Sync enriched contact info directly into your CRM and tools

Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.

Intent Signals

Buyer intent signals

CRM Enrichment

Contact Enrichment

Workflows and tasks

Workflows and tasks

Integrations

Integrations

Thousands of companies, including, are just a search away.